| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/03/2022 | 73.71% | SVB Leerink | $37 → $30 | Maintains | Outperform |
| 08/16/2022 | 148.99% | Piper Sandler | $44 → $43 | Maintains | Overweight |
| 08/05/2022 | 114.24% | SVB Leerink | $48 → $37 | Maintains | Outperform |
| 05/24/2022 | 201.1% | Wedbush | $59 → $52 | Maintains | Outperform |
| 05/20/2022 | 177.94% | SVB Leerink | $49 → $48 | Maintains | Outperform |
| 04/04/2022 | 125.83% | JP Morgan | $47 → $39 | Maintains | Overweight |
| 03/18/2022 | 73.71% | BMO Capital | $51 → $30 | Maintains | Outperform |
| 11/19/2021 | 201.1% | Piper Sandler | → $52 | Initiates Coverage On | → Overweight |
| 08/23/2021 | 183.73% | SVB Leerink | $55 → $49 | Maintains | Outperform |
| 08/09/2021 | 218.47% | SVB Leerink | $56 → $55 | Maintains | Outperform |
| 02/05/2021 | 247.42% | HC Wainwright & Co. | $58 → $60 | Maintains | Buy |
| 02/04/2021 | 224.26% | SVB Leerink | $57 → $56 | Maintains | Outperform |
| 11/17/2020 | 247.42% | BTIG | → $60 | Initiates Coverage On | → Buy |
| 11/10/2020 | 235.84% | HC Wainwright & Co. | $54 → $58 | Maintains | Buy |
| 11/06/2020 | 230.05% | BMO Capital | $51 → $57 | Maintains | Outperform |
| 10/15/2020 | 195.31% | BMO Capital | $40 → $51 | Maintains | Outperform |
| 10/15/2020 | 212.68% | HC Wainwright & Co. | $25 → $54 | Upgrades | Neutral → Buy |
| 10/15/2020 | 154.78% | SVB Leerink | $27 → $44 | Maintains | Outperform |
| 08/07/2020 | 56.34% | SVB Leerink | $25 → $27 | Maintains | Outperform |
| 07/01/2020 | 44.76% | HC Wainwright & Co. | → $25 | Downgrades | Buy → Neutral |
| 06/04/2020 | 44.76% | HC Wainwright & Co. | $24 → $25 | Maintains | Buy |
| 05/05/2020 | 21.6% | Barclays | → $21 | Initiates Coverage On | → Overweight |
| 01/21/2020 | 38.97% | HC Wainwright & Co. | $26 → $24 | Maintains | Buy |
| 09/04/2019 | 15.81% | Roth Capital | → $20 | Initiates Coverage On | → Buy |
| 07/23/2019 | 62.13% | Chardan Capital | → $28 | Initiates Coverage On | → Buy |
| 07/12/2019 | 50.55% | JP Morgan | $27 → $26 | Upgrades | Neutral → Overweight |
| 07/08/2019 | 50.55% | HC Wainwright & Co. | → $26 | Initiates Coverage On | → Buy |
| 04/25/2019 | 38.97% | Wedbush | → $24 | Initiates Coverage On | → Outperform |
| 01/23/2019 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 08/14/2018 | 79.5% | BMO Capital | → $31 | Initiates Coverage On | → Outperform |
| 08/14/2018 | 50.55% | JP Morgan | → $26 | Initiates Coverage On | → Overweight |
Replimune Group Questions & Answers
The latest price target for Replimune Group (NASDAQ: REPL) was reported by SVB Leerink on October 3, 2022. The analyst firm set a price target for $30.00 expecting REPL to rise to within 12 months (a possible 73.71% upside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for Replimune Group (NASDAQ: REPL) was provided by SVB Leerink, and Replimune Group maintained their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Replimune Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Replimune Group was filed on October 3, 2022 so you should expect the next rating to be made available sometime around October 3, 2023.
While ratings are subjective and will change, the latest Replimune Group (REPL) rating was a maintained with a price target of $37.00 to $30.00. The current price Replimune Group (REPL) is trading at is $17.27, which is out of the analyst's predicted range.